StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Provectus Biopharmaceuticals's operating margin for the twelve months ending Dec 31, 2025 was -1575.3%. For fiscal 2025 it was -1575.3%, against -734.4% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1575.3%−840.9
FY2024Dec 31, 2024-734.4%−214.2
FY2023Dec 31, 2023-520.2%−173.6
FY2022Dec 31, 2022-346.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2025Jun 30, 2025-3132.8%−2821.1
Q1 FY2025Mar 31, 2025-394.1%−206.2
Q4 FY2024Dec 31, 2024-16289.0%−15789.7
Q3 FY2024Sep 30, 2024-870.9%+153.3
Q2 FY2024Jun 30, 2024-311.7%+182.7
Q1 FY2024Mar 31, 2024-187.9%+193.7
Q4 FY2023Dec 31, 2023-499.3%−84.5
Q3 FY2023Sep 30, 2023-1024.1%−812.6
Q2 FY2023Jun 30, 2023-494.4%−159.4
Q1 FY2023Mar 31, 2023-381.5%+151.5
Q4 FY2022Dec 31, 2022-414.8%–
Q3 FY2022Sep 30, 2022-211.6%–
Q2 FY2022Jun 30, 2022-335.1%–
Q1 FY2022Mar 31, 2022-533.1%–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?